=== Sygdomsmodificerende behandlinger ===
[[Fil:Injection 23.JPG|right|thumb|Sygdomsmodificerende behandlinger er dyre, og de fleste er afhængige af hyppige (op til daglige) injektioner. Andre gives ved drop med 1-3 måneders intervaller.]]
Den tidligste kliniske fremkomst af relapserende-remitterende MS (RRMS) er klinisk isoleret syndrom (KIS). Flere studier har vist, at behandling med [[interferon]]er under et attak i begyndelsen af sygdomsforløbet kan nedsætte risikoen for, at en patient vil udvikle klinisk MS.<ref>{{cite journal |author=Jacobs LD, Beck RW, Simon JH, ''et al.'' |title=Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group |journal=[[New England Journal of Medicine|N Engl J Med]] |volume=343 |issue=13 |pages=898–904 |year=2000 |pmid=11006365 |doi=10.1056/NEJM200009283431301}}</ref><ref>{{cite journal |author=Comi G, Filippi M, Barkhof F, ''et al.'' |title=Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study |journal=[[Lancet (journal)|Lancet]] |volume=357 |issue=9268 |pages=1576–82 |year=2001 |pmid=11377645 |doi=10.1016/s0140-6736(00)04725-5 |last12=Hommes |first12=OR |last13=Early Treatment Of Multiple Sclerosis Study |first13=Group }}</ref><ref name="pmid17679016">{{cite journal |author=Kappos L, Freedman MS, Polman CH, ''et al.'' |title=Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study |journal=Lancet |volume=370 |issue=9585 |pages=389–97 |year=2007 |pmid=17679016 |doi=10.1016/S0140-6736(07)61194-5 |last12=Lanius |first12=V |last13=Pohl |first13=C |last14=Sandbrink |first14=R |last15=Benefit Study |first15=Group}}</ref>
Sygdomme Videnskab Naturvidenskab